Market Overview - The Shanghai Composite Index is at 3757.36 points, with a decline of 1.47% and total A-share trading volume of 20349.66 billion yuan [1] - As of now, 73 A-shares have surpassed their annual line, with notable stocks showing significant deviation rates [1] Notable Stocks - Stocks with the highest deviation rates include: - Aibulu (301259) with a deviation rate of 8.09% and a price increase of 10.22% [1] - Gongxiao Daji (000564) with a deviation rate of 8.06% and a price increase of 8.56% [1] - Shenglong Co. (603178) with a deviation rate of 6.11% and a price increase of 10.02% [1] - Other stocks with lower deviation rates that have just crossed the annual line include: - Weiguang Biological, Changjiang Electric Power, and Yunnan Tourism [1] Deviation Rate Rankings - The top stocks by deviation rate on September 4 include: - Aibulu (301259): Latest price 47.35 yuan, annual line 43.81 yuan [1] - Gongxiao Daji (000564): Latest price 2.79 yuan, annual line 2.58 yuan [1] - Shenglong Co. (603178): Latest price 20.54 yuan, annual line 19.36 yuan [1] - Additional stocks with notable performance include: - Wufangzhai (603237) with a deviation rate of 4.78% [1] - Yuanzhu Co. (603886) with a deviation rate of 3.50% [1]

Financial Performance - Dongfang Ocean reported a total revenue of 156 million yuan for the first half of 2025, a slight increase of 0.34% year-on-year [1] - The net profit attributable to shareholders was -71.01 million yuan, representing a significant decline of 71.23% compared to the previous year [1] - In Q2 2025, the total revenue was 80.77 million yuan, down 9.12% year-on-year, with a net profit of -48.91 million yuan, a decrease of 80.61% [1] Profitability Metrics - The gross margin was -0.92%, a decrease of 106.54% year-on-year, indicating a significant drop in profitability [1] - The net margin stood at -45.99%, down 71.51% from the previous year [1] - The total of selling, administrative, and financial expenses reached 54.57 million yuan, accounting for 34.97% of revenue, an increase of 2.36% year-on-year [1] Cash Flow and Assets - The company reported a negative operating cash flow per share of -0.03 yuan, which is an improvement of 41.54% year-on-year [1] - The net asset value per share decreased to 0.69 yuan, down 13.69% from the previous year [1] - The average return on invested capital (ROIC) over the past decade was -10.81%, with the worst year being 2022 at -674.95% [3] Financial Health Indicators - The company has faced negative net profits in 6 out of 18 annual reports since its listing, indicating a history of poor financial performance [3] - The average operating cash flow over the past three years was -132.48% relative to current liabilities, suggesting ongoing cash flow issues [3] - The accounts receivable increased by 30.99% year-on-year, reaching 79.08 million yuan, which raises concerns about the company's ability to collect payments [1]

Core Viewpoint - The company, Shandong Oriental Ocean Technology Co., Ltd., has released its 2025 semi-annual report, which reflects its operational results, financial status, and future development plans. The report indicates that there will be no cash dividends or stock bonuses distributed to shareholders during this period [3][4][5]. Company Overview - The company has confirmed that there have been no changes in its controlling shareholder or actual controller during the reporting period [5][6]. - The board of directors and the supervisory board have both approved the semi-annual report, affirming that the report complies with legal and regulatory requirements and accurately reflects the company's situation [9][16]. Financial Data and Indicators - The semi-annual report includes key financial data and indicators, although specific figures are not detailed in the provided documents [4]. Important Events - The company’s wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., has obtained a medical device registration certificate for its serum amyloid A (SAA) testing kit, which is expected to enhance its product line in clinical testing [12][14]. - The impact of this new product on the company's performance is currently uncertain, as it has not yet commenced production and its sales will depend on market demand and expansion efforts [13][14].

Core Insights - The company reported a main revenue of 156 million yuan for the first half of 2025, showing a year-on-year increase of 0.34% [1] - The net profit attributable to shareholders was -71.01 million yuan, a significant decline of 71.23% year-on-year [1] - The non-recurring net profit was -74.38 million yuan, down 57.25% compared to the previous year [1] Financial Performance - In Q2 2025, the company achieved a single-quarter main revenue of 80.77 million yuan, which is a decrease of 9.12% year-on-year [1] - The single-quarter net profit attributable to shareholders for Q2 2025 was -48.91 million yuan, reflecting an 80.61% decline year-on-year [1][4] - The single-quarter non-recurring net profit for Q2 2025 was -49.70 million yuan, down 62.34% year-on-year [1][4] Profitability Metrics - The company's debt ratio stood at 18.53% [1] - Investment income was recorded at -0.04 million yuan, with financial expenses amounting to 1.32 million yuan [1] - The gross profit margin was -0.92%, indicating a year-on-year decrease of 106.53% [7] Earnings Per Share - Earnings per share were reported at -0.04 yuan, a 100% decline year-on-year [7] - The company’s operating cash flow per share was -0.03 yuan, showing an increase of 41.53% year-on-year [7] Shareholder Information - The largest shareholder is Shenzhen Qianhai Guoyuan Private Securities Fund Management Co., Ltd., holding 200 million yuan, which accounts for 12.92% of shares [11] - Other significant shareholders include Yantai Zhengda Urban Construction Development Co., Ltd. with 67.20 million yuan (4.43%) and Shandong Dongfang Ocean Technology Co., Ltd. with 48.14 million yuan (3.17%) [11]

Group 1 - The company reported a revenue of 156,041,607.30 yuan for the first half of 2025, representing a year-on-year growth of 0.34% [2] - The net profit attributable to shareholders of the listed company was -71,014,445.28 yuan [2]

Group 1 - The company reported a revenue of 156 million yuan for the first half of 2025, representing a year-on-year growth of 0.34% [1] - The net loss attributable to shareholders of the listed company was 71.0144 million yuan, with a net loss of 74.3831 million yuan after deducting non-recurring gains and losses [1] - The basic loss per share was 0.04 yuan [1]

山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 证券代码：002086 证券简称：东方海洋 公告编号：2025-048 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 血清淀粉样蛋白 A（SAA）测定试剂盒（荧光免疫层析法）的投产及对公司业绩 的后续影响具有不确定性，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的血清淀粉样蛋白 A（SAA）测定试剂盒（荧光免疫层析 法）于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证（体 外诊断试剂），具体情况如下： 一、产品信息 1、血清淀粉样蛋白 A（SAA）测定试剂盒（荧光免疫层析法） | 产品名称 | 血清淀粉样蛋白 A（SAA）测定试剂盒（荧光免疫层析法） | | | | | | | | --- | --- | --- | --- | --- | ...

山东东方海洋科技股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | 山东东方海洋国际 | 子公司 | 其他应收款 | | | | | | 往来 | 非经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 货运代理有限公司 | | | | | | | | 款 | 性往来 | | | 东方海洋生命科技 | 子公司 | 其他应收款 | 8,306.44 | 148.48 | 1,448.86 | 50.00 | 9,853.78 | 往来 | 非经营 | | | 有限公司 | | | | | | | | 款 | 性往来 | | | 山东东方海洋销售 | 子公司 | 其他应收款 | 1,048.22 | | 117.81 | | 1,166.03 | 往来 | 非经营 | | | 有限公司 | | | | | | | | 款 | 性往来 | | | AVIOQ.INC | 子公司 | 其他应收款 | 10,911.99 | | | | 10,911.99 | 往来 | 非经营 | | ...

山东东方海洋科技股份有限公司 2025 年半年度财务报告 山东东方海洋科技股份有限公司 2025 年半年度财务报告 （未经审计） 【2025 年 08 月】 山东东方海洋科技股份有限公司 2025 年半年度财务报告 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：山东东方海洋科技股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 302,764,088.03 | 404,608,292.25 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 79,084,524.50 | 75,195,699.15 | | 应收款项融资 | | | | 预付款项 | 11,194,455.72 | 12,973,275.43 | | 应收保费 | | | | 应收分保账款 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-047 山东东方海洋科技股份有限公司 一、审议通过《公司 2025 年半年度报告及摘要》 监事会认为：董事会编制和审核《公司 2025 年半年度报告及摘要》的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：5 票同意，0 票反对，0 票弃权。 具体内容详见 2025 年 8 月 29 日刊登于巨潮资讯网（www.cninfo.com.cn）上 的《2025 年半年度报告及其摘要》；《2025 年半年度报告摘要》刊登于同日的《中 国证券报》《上海证券报》《证券时报》和《证券日报》。 特此公告。 第八届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届监事会第十二次会 议通知于 2025 年 8 月 18 日以电话、邮件等形式通知全体监事，会议定于 2025 年 8 月 28 日以通讯方式召开，应参加监事 5 人，实际参加 ...